These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 11233434)

  • 1. Genomania meets the bottom line.
    Malakoff D; Service RF
    Science; 2001 Feb; 291(5507):1193-203. PubMed ID: 11233434
    [No Abstract]   [Full Text] [Related]  

  • 2. HGS drug flop latest genomics setback.
    Reid B
    Nat Biotechnol; 2002 Jun; 20(6):533. PubMed ID: 12042841
    [No Abstract]   [Full Text] [Related]  

  • 3. Hyseq-Variagenics merger signals end of the line.
    Hodgson J
    Nat Biotechnol; 2003 Jan; 21(1):5. PubMed ID: 12511895
    [No Abstract]   [Full Text] [Related]  

  • 4. Building for an exit (or not).
    Gunning TG
    Nat Biotechnol; 2008 Sep; 26(9):971-3. PubMed ID: 18792427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. European biotechnology firms approve of stock market mergers.
    Michael A
    Nat Biotechnol; 1998 Dec; 16(13):1301. PubMed ID: 9853595
    [No Abstract]   [Full Text] [Related]  

  • 6. The other side of being CFO.
    Benner K
    Fortune; 2012 Oct; 166(6):58. PubMed ID: 23072075
    [No Abstract]   [Full Text] [Related]  

  • 7. The number on biotech indexes.
    Jacobs T
    Nat Biotechnol; 2005 Nov; 23(11):1356. PubMed ID: 16273059
    [No Abstract]   [Full Text] [Related]  

  • 8. Hidden in plain view.
    Jacobs T
    Nat Biotechnol; 2003 Jun; 21(6):603. PubMed ID: 12776141
    [No Abstract]   [Full Text] [Related]  

  • 9. The hermit crab solution.
    Silverman E
    Nat Biotechnol; 2006 Mar; 24(3):245-7. PubMed ID: 16680810
    [No Abstract]   [Full Text] [Related]  

  • 10. Healthcare stocks soar on wings of restructuring.
    Lutz S
    Mod Healthc; 1996 Jan; 26(2):3. PubMed ID: 10153952
    [No Abstract]   [Full Text] [Related]  

  • 11. Big pharma swallows biotech's pride.
    Huggett B
    Nat Biotechnol; 2008 Sep; 26(9):955-6. PubMed ID: 18779785
    [No Abstract]   [Full Text] [Related]  

  • 12. A new prescription for your portfolio.
    Clifford L; O'Keefe B; Stires D
    Fortune; 2001 Jul; 144(2):74-6, 78, 80. PubMed ID: 11471357
    [No Abstract]   [Full Text] [Related]  

  • 13. Genomics. After the gold rush: gene firms reinvent themselves.
    Gura T
    Science; 2002 Sep; 297(5589):1982-4. PubMed ID: 12242421
    [No Abstract]   [Full Text] [Related]  

  • 14. Public biotechnology 2002--the numbers.
    Lähteenmäki R; DeFrancesco L
    Nat Biotechnol; 2003 Jun; 21(6):607-12. PubMed ID: 12776143
    [No Abstract]   [Full Text] [Related]  

  • 15. Capital faucet wide-open. Firms' healthcare-related investments up 16% in first half.
    Pallarito K
    Mod Healthc; 1997 Sep; 27(35):76. PubMed ID: 10170390
    [No Abstract]   [Full Text] [Related]  

  • 16. Genomics down under. A talk with John Mattick Director of the Australian Genome Research Facility, and Co-Director of the Institute for Molecular Bioscience. Interview by Holger Breithaupt.
    Mattick J
    EMBO Rep; 2000 Sep; 1(3):204-7. PubMed ID: 11256598
    [No Abstract]   [Full Text] [Related]  

  • 17. Bridging the gap in the German economy.
    Schiermeier Q
    Nature; 2005 Aug; 436(7054):1087. PubMed ID: 16127797
    [No Abstract]   [Full Text] [Related]  

  • 18. Big biotech buys iconic genetics firm.
    Baker M
    Nature; 2012 Dec; 492(7429):321. PubMed ID: 23257857
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmas partner in venture seeking drug discovery tools.
    Mack GS
    Nat Biotechnol; 2008 Sep; 26(9):960-1. PubMed ID: 18779790
    [No Abstract]   [Full Text] [Related]  

  • 20. More than meets the eyes?
    Jacobs T
    Nat Biotechnol; 2004 Oct; 22(10):1221. PubMed ID: 15470455
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.